SynthesisPharmacology2026
Safety and Efficacy of Efbemalenograstim Alfa for Patients at Risk for Chemotherapy-Induced Neutropenia: A Systematic Review and Meta-Analysis.
Synthesis in Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChemotherapy-induced neutropenia (CIN) and its severe complication, febrile neutropenia, remain major challenges in oncology. Although granulocyte colony-stimulating factors (G-CSFs) have reduced the incidence of these complications, limitations related to dosing schedules, polyethylene glycol (PEG)-associated concerns, and pharmacokinetic variability persist. Efbemalenograstim alfa (F-627) is a novel non-PEGylated Fc fusion G-CSF designed for once-per-cycle administration. This systematic review and meta-analysis evaluated the efficacy and safety of efbemalenograstim alfa compared with placebo or standard G-CSFs in patients at risk of CIN.
methodsA systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD42024628001). MEDLINE, Embase, Cochrane Library, Web of Science, and <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> were searched from inception to October 22, 2025. Randomized controlled trials evaluating efbemalenograstim alfa in patients receiving myelotoxic chemotherapy were included. Efficacy outcomes included duration of severe neutropenia (DSN), incidence of severe neutropenia (ISN), and depth of absolute neutrophil count (ANC) nadir. Safety outcomes included adverse events, serious adverse events, and treatment discontinuations. Random-effects meta-analyses were performed.
resultsFive randomized controlled trials involving approximately 800 patients with breast cancer receiving myelotoxic chemotherapy were included. Compared with placebo or standard G-CSFs, efbemalenograstim alfa demonstrated comparable efficacy in reducing DSN during the first chemotherapy cycle (MD -0.32 days; 95% CI: -0.79 to 0.14) and ISN (RR 0.86; 95% CI: 0.73-1.03). A significant improvement in ANC nadir was observed (MD + 0.40 ×109/L; p = 0.0002). Rates of serious adverse events (RR 0.71; 95% CI: 0.29-1.70), adverse events, and treatment discontinuations were comparable between groups. Heterogeneity was primarily attributable to the inclusion of a placebo-controlled study.
conclusionEfbemalenograstim alfa demonstrated efficacy and safety comparable to currently available long-acting G-CSFs for the prevention of CIN. Its Fc fusion structure enables once-per-cycle administration without PEGylation, supporting its potential as an alternative long-acting G-CSF. Further studies are needed to evaluate long-term outcomes and real-world effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.